-
1
-
-
0034680102
-
Molecular portraits of human breast tumours
-
COI: 1:CAS:528:DC%2BD3cXmt1CnsLw%3D, PID: 1096360
-
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi:10.1038/35021093
-
(2000)
Nature
, vol.406
, Issue.6797
, pp. 747-752
-
-
Perou, C.M.1
Sorlie, T.2
Eisen, M.B.3
van de Rijn, M.4
Jeffrey, S.S.5
Rees, C.A.6
Pollack, J.R.7
Ross, D.T.8
Johnsen, H.9
Akslen, L.A.10
Fluge, O.11
Pergamenschikov, A.12
Williams, C.13
Zhu, S.X.14
Lonning, P.E.15
Borresen-Dale, A.L.16
Brown, P.O.17
Botstein, D.18
-
2
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
COI: 1:CAS:528:DC%2BD3MXntVGmsbo%3D, PID: 1155381
-
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi:10.1073/pnas.191367098
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, Issue.19
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
Aas, T.4
Geisler, S.5
Johnsen, H.6
Hastie, T.7
Eisen, M.B.8
van de Rijn, M.9
Jeffrey, S.S.10
Thorsen, T.11
Quist, H.12
Matese, J.C.13
Brown, P.O.14
Botstein, D.15
Lonning, P.E.16
Borresen-Dale, A.L.17
-
3
-
-
79953307884
-
Risk factors for relapse after conservative treatment in T1–T2 breast cancer with one to three positive axillary nodes: results of an observational study
-
COI: 1:STN:280:DC%2BC3MzkvV2kug%3D%3D, PID: 2104804
-
Aristei C, Leonardi C, Stracci F, Palumbo I, Luini A, Viale G, Cristallini EG, Cavaliere A, Orecchia R (2011) Risk factors for relapse after conservative treatment in T1–T2 breast cancer with one to three positive axillary nodes: results of an observational study. Ann Oncol 22(4):842–847. doi:10.1093/annonc/mdq470
-
(2011)
Ann Oncol
, vol.22
, Issue.4
, pp. 842-847
-
-
Aristei, C.1
Leonardi, C.2
Stracci, F.3
Palumbo, I.4
Luini, A.5
Viale, G.6
Cristallini, E.G.7
Cavaliere, A.8
Orecchia, R.9
-
4
-
-
0042208398
-
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy
-
COI: 1:CAS:528:DC%2BD3sXmvFSqt74%3D, PID: 1289732
-
Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8(4):307–325
-
(2003)
Oncologist
, vol.8
, Issue.4
, pp. 307-325
-
-
Ross, J.S.1
Fletcher, J.A.2
Linette, G.P.3
Stec, J.4
Clark, E.5
Ayers, M.6
Symmans, W.F.7
Pusztai, L.8
Bloom, K.J.9
-
5
-
-
84939979930
-
Impact of breast cancer subtypes and patterns of metastasis on outcome
-
COI: 1:CAS:528:DC%2BC2MXkvVSjs7s%3D, PID: 2578318
-
Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, Werner C, Klug SJ, Werner A, Gatzweiler A, Richter B, Baretton G, Wimberger P (2015) Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat 150(3):621–629. doi:10.1007/s10549-015-3341-3
-
(2015)
Breast Cancer Res Treat
, vol.150
, Issue.3
, pp. 621-629
-
-
Kast, K.1
Link, T.2
Friedrich, K.3
Petzold, A.4
Niedostatek, A.5
Schoffer, O.6
Werner, C.7
Klug, S.J.8
Werner, A.9
Gatzweiler, A.10
Richter, B.11
Baretton, G.12
Wimberger, P.13
-
6
-
-
0034612344
-
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
-
COI: 1:CAS:528:DC%2BD3cXktFaiurY%3D, PID: 1084157
-
Minuzzo M, Marchini S, Broggini M, Faircloth G, D’Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97(12):6780–6784
-
(2000)
Proc Natl Acad Sci USA
, vol.97
, Issue.12
, pp. 6780-6784
-
-
Minuzzo, M.1
Marchini, S.2
Broggini, M.3
Faircloth, G.4
D’Incalci, M.5
Mantovani, R.6
-
7
-
-
0035146702
-
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
-
COI: 1:CAS:528:DC%2BD3MXntlOntQ%3D%3D, PID: 1116513
-
Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D’Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37(1):97–105
-
(2001)
Eur J Cancer
, vol.37
, Issue.1
, pp. 97-105
-
-
Erba, E.1
Bergamaschi, D.2
Bassano, L.3
Damia, G.4
Ronzoni, S.5
Faircloth, G.T.6
D’Incalci, M.7
-
8
-
-
0037074625
-
A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions
-
COI: 1:CAS:528:DC%2BD38XlsVGhsQ%3D%3D, PID: 1183189
-
Marco E, Garcia-Nieto R, Mendieta J, Manzanares I, Cuevas C, Gago F (2002) A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J Med Chem 45(4):871–880
-
(2002)
J Med Chem
, vol.45
, Issue.4
, pp. 871-880
-
-
Marco, E.1
Garcia-Nieto, R.2
Mendieta, J.3
Manzanares, I.4
Cuevas, C.5
Gago, F.6
-
9
-
-
84955752571
-
-
D’Incalci M, Zambelli A (2015) Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs (in press
-
D’Incalci M, Zambelli A (2015) Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs (in press)
-
-
-
-
10
-
-
33745259879
-
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
-
COI: 1:CAS:528:DC%2BD28XltVOmtLk%3D, PID: 1673602
-
Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL (2006) A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94(11):1610–1614
-
(2006)
Br J Cancer
, vol.94
, Issue.11
, pp. 1610-1614
-
-
Zelek, L.1
Yovine, A.2
Brain, E.3
Turpin, F.4
Taamma, A.5
Riofrio, M.6
Spielmann, M.7
Jimeno, J.8
Misset, J.L.9
-
11
-
-
84910646290
-
Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens
-
COI: 1:CAS:528:DC%2BC2cXhsV2nsbnE, PID: 2523922
-
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B (2014) Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens. Clin Breast Cancer 14(6):396–404. doi:10.1016/j.clbc.2014.06.006
-
(2014)
Clin Breast Cancer
, vol.14
, Issue.6
, pp. 396-404
-
-
Goldstein, L.J.1
Gurtler, J.2
Del Prete, S.A.3
Tjulandin, S.4
Semiglazov, V.F.5
Bayever, E.6
Michiels, B.7
-
12
-
-
17944374027
-
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair
-
COI: 1:CAS:528:DC%2BD3MXlvVOrs7c%3D, PID: 1147963
-
Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y (2001) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7(8):961–966
-
(2001)
Nat Med
, vol.7
, Issue.8
, pp. 961-966
-
-
Takebayashi, Y.1
Pourquier, P.2
Zimonjic, D.B.3
Nakayama, K.4
Emmert, S.5
Ueda, T.6
Urasaki, Y.7
Kanzaki, A.8
Akiyama, S.I.9
Popescu, N.10
Kraemer, K.H.11
Pommier, Y.12
-
13
-
-
0035874074
-
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
-
COI: 1:CAS:528:DC%2BD3MXjs1eitL4%3D, PID: 1130469
-
Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D’Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92(4):583–588
-
(2001)
Int J Cancer
, vol.92
, Issue.4
, pp. 583-588
-
-
Damia, G.1
Silvestri, S.2
Carrassa, L.3
Filiberti, L.4
Faircloth, G.T.5
Liberi, G.6
Foiani, M.7
D’Incalci, M.8
-
14
-
-
41549100818
-
DNA repair functionality appears to modulate the clinical outcome of advanced sarcoma patients treated with Yondelis (ET-743)
-
Schöffski P, Casali PG, Taron M, van Oosterom AT, Judson I, Grosso F, Blay JY, Maki B, Tercero JC, Jimeno J, Rosell R (2006) DNA repair functionality appears to modulate the clinical outcome of advanced sarcoma patients treated with Yondelis (ET-743). J Clin Oncol 24(18S):9522
-
(2006)
J Clin Oncol
, vol.24
, Issue.18S
, pp. 9522
-
-
Schöffski, P.1
Casali, P.G.2
Taron, M.3
van Oosterom, A.T.4
Judson, I.5
Grosso, F.6
Blay, J.Y.7
Maki, B.8
Tercero, J.C.9
Jimeno, J.10
Rosell, R.11
-
15
-
-
84903900546
-
Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
-
COI: 1:STN:280:DC%2BC2crps1Cntw%3D%3D, PID: 2469257
-
Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Goncalves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M, Lubinski J (2014) Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 25(6):1152–1158. doi:10.1093/annonc/mdu134
-
(2014)
Ann Oncol
, vol.25
, Issue.6
, pp. 1152-1158
-
-
Delaloge, S.1
Wolp-Diniz, R.2
Byrski, T.3
Blum, J.L.4
Goncalves, A.5
Campone, M.6
Lardelli, P.7
Kahatt, C.8
Nieto, A.9
Cullell-Young, M.10
Lubinski, J.11
-
16
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
COI: 1:STN:280:DC%2BD3c7it1Gitg%3D%3D, PID: 1065543
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.3
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
17
-
-
0018687930
-
A multiple testing procedure for clinical trials
-
PID: 49734
-
O’Brien PC, Fleming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35(3):549–556
-
(1979)
Biometrics
, vol.35
, Issue.3
, pp. 549-556
-
-
O’Brien, P.C.1
Fleming, T.R.2
-
18
-
-
70449529019
-
Discrete sequential boundaries for clinical trials
-
Lan KKG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70(3):659–663
-
(1983)
Biometrika
, vol.70
, Issue.3
, pp. 659-663
-
-
Lan, K.K.G.1
DeMets, D.L.2
-
19
-
-
34247569300
-
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry
-
PID: 1738771
-
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728. doi:10.1002/cncr.22618
-
(2007)
Cancer
, vol.109
, Issue.9
, pp. 1721-1728
-
-
Bauer, K.R.1
Brown, M.2
Cress, R.D.3
Parise, C.A.4
Caggiano, V.5
-
20
-
-
84867859783
-
Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
-
PID: 2254464
-
Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463–5472. doi:10.1002/cncr.27581
-
(2012)
Cancer
, vol.118
, Issue.22
, pp. 5463-5472
-
-
Lin, N.U.1
Vanderplas, A.2
Hughes, M.E.3
Theriault, R.L.4
Edge, S.B.5
Wong, Y.N.6
Blayney, D.W.7
Niland, J.C.8
Winer, E.P.9
Weeks, J.C.10
-
21
-
-
77957706438
-
The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer
-
PID: 2081481
-
Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, Sabri S, Abdulkarim B (2010) The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 124(1):187–194. doi:10.1007/s10549-010-1135-1
-
(2010)
Breast Cancer Res Treat
, vol.124
, Issue.1
, pp. 187-194
-
-
Gabos, Z.1
Thoms, J.2
Ghosh, S.3
Hanson, J.4
Deschenes, J.5
Sabri, S.6
Abdulkarim, B.7
-
22
-
-
67349148556
-
Pattern of metastatic spread in triple-negative breast cancer
-
PID: 1854309
-
Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009) Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 115(2):423–428. doi:10.1007/s10549-008-0086-2
-
(2009)
Breast Cancer Res Treat
, vol.115
, Issue.2
, pp. 423-428
-
-
Dent, R.1
Hanna, W.M.2
Trudeau, M.3
Rawlinson, E.4
Sun, P.5
Narod, S.A.6
-
23
-
-
78751610848
-
Iniparib plus chemotherapy in metastatic triple-negative breast cancer
-
PID: 2120810
-
O’Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, Koo IC, Sherman BM, Bradley C (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364(3):205–214. doi:10.1056/NEJMoa1011418
-
(2011)
N Engl J Med
, vol.364
, Issue.3
, pp. 205-214
-
-
O’Shaughnessy, J.1
Osborne, C.2
Pippen, J.E.3
Yoffe, M.4
Patt, D.5
Rocha, C.6
Koo, I.C.7
Sherman, B.M.8
Bradley, C.9
-
24
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
COI: 1:CAS:528:DC%2BD3MXisVGktrc%3D, PID: 1124815
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101
-
(2001)
N Engl J Med
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
25
-
-
84879788003
-
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
-
PID: 2335256
-
Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22(4):525–531. doi:10.1016/j.breast.2012.12.006
-
(2013)
Breast
, vol.22
, Issue.4
, pp. 525-531
-
-
Olson, E.M.1
Najita, J.S.2
Sohl, J.3
Arnaout, A.4
Burstein, H.J.5
Winer, E.P.6
Lin, N.U.7
-
26
-
-
84863724882
-
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
-
PID: 2214707
-
Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133(3):831–841. doi:10.1007/s10549-011-1891-6
-
(2012)
Breast Cancer Res Treat
, vol.133
, Issue.3
, pp. 831-841
-
-
Lowery, A.J.1
Kell, M.R.2
Glynn, R.W.3
Kerin, M.J.4
Sweeney, K.J.5
-
27
-
-
84923052492
-
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer
-
COI: 1:CAS:528:DC%2BC2MXktF2rs7k%3D, PID: 2569301
-
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J, Group CS (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. doi:10.1056/NEJMoa1413513
-
(2015)
N Engl J Med
, vol.372
, Issue.8
, pp. 724-734
-
-
Swain, S.M.1
Baselga, J.2
Kim, S.B.3
Ro, J.4
Semiglazov, V.5
Campone, M.6
Ciruelos, E.7
Ferrero, J.M.8
Schneeweiss, A.9
Heeson, S.10
Clark, E.11
Ross, G.12
Benyunes, M.C.13
Cortes, J.14
Group, C.S.15
-
28
-
-
84923205214
-
Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
-
COI: 1:CAS:528:DC%2BC2MXktlCntrc%3D, PID: 2560586
-
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594–601. doi:10.1200/JCO.2013.52.4892
-
(2015)
J Clin Oncol
, vol.33
, Issue.6
, pp. 594-601
-
-
Kaufman, P.A.1
Awada, A.2
Twelves, C.3
Yelle, L.4
Perez, E.A.5
Velikova, G.6
Olivo, M.S.7
He, Y.8
Dutcus, C.E.9
Cortes, J.10
-
29
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
COI: 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D, PID: 1719253
-
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733–2743. doi:10.1056/NEJMoa064320
-
(2006)
N Engl J Med
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
Jagiello-Gruszfeld, A.7
Crown, J.8
Chan, A.9
Kaufman, B.10
Skarlos, D.11
Campone, M.12
Davidson, N.13
Berger, M.14
Oliva, C.15
Rubin, S.D.16
Stein, S.17
Cameron, D.18
-
30
-
-
65349110371
-
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study
-
von Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27(12):1999–2006. doi:10.1200/JCO.2008.19.6618
-
(2009)
J Clin Oncol
, vol.27
, Issue.12
, pp. 1999-2006
-
-
von Minckwitz, G.1
du Bois, A.2
Schmidt, M.3
Maass, N.4
Cufer, T.5
de Jongh, F.E.6
Maartense, E.7
Zielinski, C.8
Kaufmann, M.9
Bauer, W.10
Baumann, K.H.11
Clemens, M.R.12
Duerr, R.13
Uleer, C.14
Andersson, M.15
Stein, R.C.16
Nekljudova, V.17
Loibl, S.18
-
31
-
-
84864066561
-
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study
-
COI: 1:CAS:528:DC%2BC38Xht1ygsr7N, PID: 2268980
-
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585–2592. doi:10.1200/JCO.2011.35.6725
-
(2012)
J Clin Oncol
, vol.30
, Issue.21
, pp. 2585-2592
-
-
Blackwell, K.L.1
Burstein, H.J.2
Storniolo, A.M.3
Rugo, H.S.4
Sledge, G.5
Aktan, G.6
Ellis, C.7
Florance, A.8
Vukelja, S.9
Bischoff, J.10
Baselga, J.11
O’Shaughnessy, J.12
-
32
-
-
70249101414
-
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules
-
COI: 1:CAS:528:DC%2BD1MXhtF2jtLrL, PID: 1965206
-
Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gomez J, Park YC, Le Cesne A (2009) Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 27(25):4188–4196
-
(2009)
J Clin Oncol
, vol.27
, Issue.25
, pp. 4188-4196
-
-
Demetri, G.D.1
Chawla, S.P.2
von Mehren, M.3
Ritch, P.4
Baker, L.H.5
Blay, J.Y.6
Hande, K.R.7
Keohan, M.L.8
Samuels, B.L.9
Schuetze, S.10
Lebedinsky, C.11
Elsayed, Y.A.12
Izquierdo, M.A.13
Gomez, J.14
Park, Y.C.15
Le Cesne, A.16
-
33
-
-
46749092063
-
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
-
PID: 1851878
-
Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT (2008) Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 9(9):1609–1618. doi:10.1517/14656566.9.9.1609
-
(2008)
Expert Opin Pharmacother
, vol.9
, Issue.9
, pp. 1609-1618
-
-
Schoffski, P.1
Dumez, H.2
Wolter, P.3
Stefan, C.4
Wozniak, A.5
Jimeno, J.6
Van Oosterom, A.T.7
-
34
-
-
24944460785
-
Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
-
COI: 1:CAS:528:DC%2BD2MXhtVersr%2FM, PID: 1611000
-
Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD (2005) Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23(24):5484–5492
-
(2005)
J Clin Oncol
, vol.23
, Issue.24
, pp. 5484-5492
-
-
Garcia-Carbonero, R.1
Supko, J.G.2
Maki, R.G.3
Manola, J.4
Ryan, D.P.5
Harmon, D.6
Puchalski, T.A.7
Goss, G.8
Seiden, M.V.9
Waxman, A.10
Quigley, M.T.11
Lopez, T.12
Sancho, M.A.13
Jimeno, J.14
Guzman, C.15
Demetri, G.D.16
-
35
-
-
81055124701
-
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
-
COI: 1:STN:280:DC%2BC38zlvV2mug%3D%3D, PID: 2193068
-
Michaelson MD, Bellmunt J, Hudes GR, Goel S, Lee RJ, Kantoff PW, Stein CA, Lardelli P, Pardos I, Kahatt C, Nieto A, Cullell-Young M, Lewis NL, Smith MR (2012) Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol 23(5):1234–1240. doi:10.1093/annonc/mdr399
-
(2012)
Ann Oncol
, vol.23
, Issue.5
, pp. 1234-1240
-
-
Michaelson, M.D.1
Bellmunt, J.2
Hudes, G.R.3
Goel, S.4
Lee, R.J.5
Kantoff, P.W.6
Stein, C.A.7
Lardelli, P.8
Pardos, I.9
Kahatt, C.10
Nieto, A.11
Cullell-Young, M.12
Lewis, N.L.13
Smith, M.R.14
-
36
-
-
84860516956
-
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum
-
PID: 2219761
-
Massuti B, Cobo M, Camps C, Domine M, Provencio M, Alberola V, Vinolas N, Rosell R, Taron M, Gutierrez-Calderon V, Lardelli P, Alfaro V, Nieto A, Isla D (2012) Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer 76(3):354–361. doi:10.1016/j.lungcan.2011.12.002
-
(2012)
Lung Cancer
, vol.76
, Issue.3
, pp. 354-361
-
-
Massuti, B.1
Cobo, M.2
Camps, C.3
Domine, M.4
Provencio, M.5
Alberola, V.6
Vinolas, N.7
Rosell, R.8
Taron, M.9
Gutierrez-Calderon, V.10
Lardelli, P.11
Alfaro, V.12
Nieto, A.13
Isla, D.14
-
37
-
-
84857530639
-
Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma
-
COI: 1:STN:280:DC%2BC383mtFWmsw%3D%3D, PID: 2164251
-
Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Perez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, Blay JY (2012) Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 23(3):771–776. doi:10.1093/annonc/mdr265
-
(2012)
Ann Oncol
, vol.23
, Issue.3
, pp. 771-776
-
-
Gronchi, A.1
Bui, B.N.2
Bonvalot, S.3
Pilotti, S.4
Ferrari, S.5
Hohenberger, P.6
Hohl, R.J.7
Demetri, G.D.8
Le Cesne, A.9
Lardelli, P.10
Perez, I.11
Nieto, A.12
Tercero, J.C.13
Alfaro, V.14
Tamborini, E.15
Blay, J.Y.16
-
38
-
-
84873351398
-
Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials
-
PID: 2339708
-
Del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gomez J, Parekh T, Park YC, McMeekin S (2013) Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol 30(1):435. doi:10.1007/s12032-012-0435-1
-
(2013)
Med Oncol
, vol.30
, Issue.1
, pp. 435
-
-
Del Campo, J.M.1
Sessa, C.2
Krasner, C.N.3
Vermorken, J.B.4
Colombo, N.5
Kaye, S.6
Gore, M.7
Zintl, P.8
Gomez, J.9
Parekh, T.10
Park, Y.C.11
McMeekin, S.12
|